Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects

European Journal of Clinical Investigation

Volumn 33, Issue 4, 2003, Pages 316-322

  Ludvik, Bernhard ^a   Thomaseth, K ^b   Nolan, J J ^c,d   Clodi, M ^a   Prager, R ^a   Pacini, G ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Institute of Biomedical Engineering   (Italy)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

Amylin; Circulatory model; Glucagon; OGL; Postprandial state

Indexed keywords

AMYLIN; GLUCAGON; GLUCOSE; INDOCYANINE GREEN; INSULIN;

ADULT; ARTERY CATHETERIZATION; ARTICLE; ASSAY; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMORAL ARTERY; GLUCAGON RELEASE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; HEPATIC VEIN; HORMONE RELEASE; HUMAN; INSULIN RESISTANCE; MALE; MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; VEIN CATHETERIZATION;

ADULT; AMYLOID; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED;

EID: 0345816796     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01142.x     Document Type: Article

References (32)

1. Fery F, Balasse EO. Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM. Diabetes 1994;43:1418-25.
2. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987;84:8628-32.
3. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987;84:3881-5.
4. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991;34:52-4.
5. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 1991;40:1615-9.
6. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995;38:642-8.
7. Arnelo U, Reidelberger R, Adrian TE, Larsson J, Permert J. Sufficiency of postprandial plasma levels of islet amyloid polypeptide for suppression of feeding in rats. Am J Physiol 1998;275:R1537-42.
8. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 1997;46:67-70.
9. Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 1999;48:935-41.
10. Olefsky J. Insulin resistance and insulin action: an in vitro and in vivo perspective. Diabetes 1981;34:121-6.
11. Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGL. Am J Physiol Endocrinol Metab 2001;281:E966-74.
12. Rowell LB, Blackmon JR, Bruce RA. Indocyanine green clearance and estimated hepatic blood flow during mild to maximal exercise in upright man. J Clin Invest 1964;43:1677-90.
13. Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971;33:732-8.
14. Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kuzuya H et al. Characterization of seven C-peptide sera. Diabetes 1978;27 (Suppl. 1):170-7.
15. Unger R, Eisenhart A, McCall M, Madison L. Glucagon antibodies and an immunoassay for glucagon. J Clin Invest 1961;48:1280-9.
16. Hartter E, Svoboda T, Lell B, Schuller M, Ludvik B, Woloszczuk W et al. Reduced islet-amyloid polypeptide in insulin-dependent diabetes mellitus. Lancet 1990;335:854.
17. Gasic S, Kleinbloesem CH, Heinz G, Waldhäusl W. Contribution of splanchnic and peripheral vascular tissues to the disposal of angiotensin-II and to regional conversion rates of angiotensin-I: a pilot study in humans. J Cardiovasc Pharmacol 1991;17:615-20.
18. Rubenstein AH, Pottenger LA, Mako M, Getz GS, Steiner DF. The metabolism of proinsulin and insulin by the liver. J Clin Invest 1971;51:912-21.
19. Kahn S, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by B cells. Diabetes 1990;39:634-8.
20. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G. Integrated mathematical model to assess beta-cell activity during the oral glucose test. Am J Physiol 1996;270:E522-31.
21. Clodi M, Thomaseth K, Pacini G, Hermann K, Kautzky-Willer A, Waldhäusl W et al. Distribution and kinetics of amylm in humans. Am J Physiol 1998;274:E903-8.
22. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C et al. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 1994;37:188-94.
23. Thomaseth K, Pacini G, Clodi M, Kautzky-Willer A, Nolan JJ, Prager R et al. Amylin release during oral glucose tolerance test. Diabet Med 1997;14 (Suppl. 2):S29-34.
24. Unger R, Orci L. Glucagon. In: Rifkin H, Porte DJ, editors. Diabetes Mellitus: Theory and Practice. NewYork, Amsterdam, London: Elsevier;1990.pp.104-20.
25. Orskov L, Nyholm B, Yde Hove K, Gravholt CH, Moller N, Schmitz O. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects. Diabet Med 1999;16:867-74.
26. Silvestre RA, Peiro E, Degano P, Miralles P, Marco J. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 1990;31:23-31.
27. Wang F, Adrian TE, Westermark GT, Ding X, Gasslander T, Permert J. Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. Am J Physiol 1999;276:E19-24.
28. Jodka C, Green D, Young AA, Gedulin B. Amylin modulation of gastric emptying in rats depends upon an intact vagus. Diabetes 1996;45 (Suppl. 1):235A.
29. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 1994;62:553-67.
30. Dinneen SF. The postprandial state: mechanisms of glucose intolerance. Diabet Med 1997;14 (Suppl. 3):S19-24.
31. Butler PC, Rizza RA. Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 1991;40:73-81.
32. Cummins AJ. Absorption of glucose and methionine from the human intestine: influence of the glucose concentration in the blood and the intestinal lumen. J Clin Invest 1952;31:928-37.